• Myrna Candelaria, Nancy Reynoso-Noverón, Mayra Ponce, Rodrigo Castillo-Llanos, Diana Nolasco-Medina, and David Cantú-De-Leon.
• Clinical Research Division, Instituto Nacional de Cancerología, Mexico City, Mexico.
• Rev Invest Clin. 2018 Jan 1; 70 (1): 46-52.

BackgroundAvailable prognosis scores for patients with diffuse large B-cell lymphoma (DLBCL) included a limited number of patients ≥ 65 years of age, and most of them did not include comorbidities. Here, we propose a prognostic score for overall survival (OS) for this group of patients.Materials And MethodsPatients ≥ 65 years with DLBCL treated at a single national reference center were included. Clinical features including comorbidities and biochemical parameters were analyzed.ResultsWe included 141 patients. Response rate in the whole group was 77%. Based on multivariate analysis, the presence of the European Cooperative Oncology Group (ECOG) > 2, elevated levels of beta-2 microglobulin, bulky disease, and anemia (hemoglobin < 10 g/dL) had a significant effect on OS. These parameters were considered when computing the prognostic score, which identified three groups with differential survival: Low, intermediate, and high risk of death, with a probability of survival at 60 months of 80.05%, 55.5%, and 29.84%, respectively.DiscussionThis score may select patients to optimize treatment. The presence of high levels of beta-2 microglobulin, bulky disease, and hemoglobin < 10 g/dL, and ECOG > 2 was associated with poor OS in elderly patients with DLBCL.Copyright: © 2017 SecretarÍa de Salud.

18 keywords...

hide…